People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. | — | Biotechnology | Series D+ | $181.8M | $1.6B | 2012 |
Sharon M. Rowland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sharon M. Rowland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| EUGENE A. BAUER | 1 | 7 |
| Sol J. Barer | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| Phil Gutry | 1 | 4 |
| Christopher Sullivan | 1 | 3 |
| Isaac A. Blech | 1 | 3 |
| Behshad Sheldon | 1 | 3 |
| ULI HACKSELL | 1 | 3 |
| Magnus Persson | 1 | 3 |
| Frank A. Torti | 1 | 3 |
| Eugene Bauer | 1 | 3 |
| Isaac M. Blech | 1 | 2 |
| Gilla Kaplan, Ph.D. | 1 | 2 |
| John Kaiser | 1 | 2 |
| Thomas Aasen | 1 | 2 |
| Mariam Morris | 1 | 2 |
| Federica F. O'Brien | 1 | 1 |
| Reza M. Mazhari | 1 | 1 |
| Eugene M. Bauer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.